









Markets
/
Stocks
/
nasdaq-toi
/

Oncology Institute Inc

TOI

3.240USD

+0.250+8.36%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

302.23MMarket Cap

LossP/E TTM



Oncology Institute Inc

3.240

+0.250+8.36%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

48 / 72

Overall Ranking

257 / 4723

Industry

Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

7.000

Target Price

+133.33%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at 83 clinic locations across 15 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion and dispensary, radiation, programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. It also provides management services to 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 55.82% year-on-year.

Undervalued

The company’s latest PE is -4.46, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 39.72M shares, decreasing 33.08% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.28M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 7.00, which is lower than the Healthcare Providers & Services industry's average of 7.42. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 119.80M, representing a year-over-year increase of 21.53%, while its net profit experienced a year-over-year increase of 10.35%.

Score

Industry at a Glance

Previous score

7.00

Change



Financials

5.55

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.16

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.41

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.68

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.20

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.20, which is lower than the Healthcare Providers & Services industry's average of 2.35. Its current P/E ratio is -4.46, which is -84.38% below the recent high of -0.70 and 49.33% above the recent low of -2.26.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 48/72

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.67, which is higher than the Healthcare Providers & Services industry's average of 7.58. The average price target for Oncology Institute Inc is 7.00, with a high of 8.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

7.000

Target Price

+134.11%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Oncology Institute Inc

TOI

CVS Health Corp

CVS

HCA Healthcare Inc

HCA

Teladoc Health Inc

TDOC

Tenet Healthcare Corp

THC

Natera Inc

NTRA

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.55, which is lower than the Healthcare Providers & Services industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 3.63 and the support level at 2.65, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.55

Change

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.040

Sell

RSI(14)

46.396

Neutral

STOCH(KDJ)(9,3,3)

37.636

Buy

ATR(14)

0.199

Low Volatility

CCI(14)

-23.017

Neutral

Williams %R

48.673

Neutral

TRIX(12,20)

-0.791

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

3.080

Buy

MA10

3.148

Buy

MA20

3.300

Sell

MA50

3.540

Sell

MA100

3.108

Buy

MA200

1.990

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Providers & Services industry's average of 8.03. The latest institutional shareholding proportion is 44.51%, representing a quarter-over-quarter decrease of 14.47%. The largest institutional shareholder is The Vanguard, holding a total of 4.28M shares, representing 4.58% of shares outstanding, with 97.65% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

M33 Growth LLC

13.75M

-4.67%

The Vanguard Group, Inc.

Star Investors

1.75M

-0.21%

OncologyCare Partners LLC

4.11M

TIFF Advisory Services, Inc.

2.98M

Deerfield Management Company, L.P.

3.36M

BlackRock Institutional Trust Company, N.A.

252.19K

+2.86%

Balyasny Asset Management LP

2.15M

+24.44%

Geode Capital Management, L.L.C.

385.75K

+11.06%

Virnich (Daniel)

1.18M

-1.69%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.13, which is lower than the Healthcare Providers & Services industry's average of 4.17. The company's beta value is 0.10. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.